Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study

M Nardin; M Verdoia; P Pergolini; Roberta ROLLA; L Barbieri; A Schaffer; Paolo MARINO; Giorgio BELLOMO; H Suryapranata; GIUSEPPE DE LUCA

doi:10.1016/j.numecd.2016.03.001

Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study

M Nardin
, M Verdoia
, P Pergolini
, Roberta ROLLA
, L Barbieri
, A Schaffer
, Paolo MARINO
, Giorgio BELLOMO
, H Suryapranata
, GIUSEPPE DE LUCA

Department of Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits. However, ticagrelor treatment has been associated with a potential increase in the serum uric acid (SUA) levels, which may influence endothelial dysfunction and prothrombotic status, thereby affecting the risk of acute cardiovascular events in patients requiring dual antiplatelet therapy (DAPT). The present study aimed to compare the impact of antiplatelet agents such as ticagrelor or clopidogrel on SUA levels and their effect on platelet reactivity.

Original language	English
Pages (from-to)	567-574
Number of pages	8
Journal	NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
Volume	26
Issue number	7
DOIs	https://doi.org/10.1016/j.numecd.2016.03.001
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Clopidogrel
Platelet aggregation
Serum uric acid
Ticagrelor

Access to Document

10.1016/j.numecd.2016.03.001

http://hdl.handle.net/11579/75748

Cite this

Nardin, M., Verdoia, M., Pergolini, P., ROLLA, R., Barbieri, L., Schaffer, A., MARINO, P., BELLOMO, G., Suryapranata, H., & DE LUCA, GIUSEPPE. (2016). Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 26(7), 567-574. https://doi.org/10.1016/j.numecd.2016.03.001

@article{569a0d3128c04a34a94c505d4d66feb4,

title = "Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study",

abstract = "New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits. However, ticagrelor treatment has been associated with a potential increase in the serum uric acid (SUA) levels, which may influence endothelial dysfunction and prothrombotic status, thereby affecting the risk of acute cardiovascular events in patients requiring dual antiplatelet therapy (DAPT). The present study aimed to compare the impact of antiplatelet agents such as ticagrelor or clopidogrel on SUA levels and their effect on platelet reactivity.",

keywords = "Clopidogrel, Platelet aggregation, Serum uric acid, Ticagrelor, Clopidogrel, Platelet aggregation, Serum uric acid, Ticagrelor",

author = "M Nardin and M Verdoia and P Pergolini and Roberta ROLLA and L Barbieri and A Schaffer and Paolo MARINO and Giorgio BELLOMO and H Suryapranata and \{DE LUCA\}, GIUSEPPE",

note = "Publisher Copyright: {\textcopyright} 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University.",

year = "2016",

doi = "10.1016/j.numecd.2016.03.001",

language = "English",

volume = "26",

pages = "567--574",

journal = "NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES",

issn = "1590-3729",

number = "7",

}

Nardin, M, Verdoia, M, Pergolini, P, ROLLA, R, Barbieri, L, Schaffer, A, MARINO, P, BELLOMO, G, Suryapranata, H & DE LUCA, GIUSEPPE 2016, 'Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study', NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, vol. 26, no. 7, pp. 567-574. https://doi.org/10.1016/j.numecd.2016.03.001

TY - JOUR

T1 - Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study

AU - Nardin, M

AU - Verdoia, M

AU - Pergolini, P

AU - ROLLA, Roberta

AU - Barbieri, L

AU - Schaffer, A

AU - MARINO, Paolo

AU - BELLOMO, Giorgio

AU - Suryapranata, H

AU - DE LUCA, GIUSEPPE

N1 - Publisher Copyright: © 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University.

PY - 2016

Y1 - 2016

N2 - New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits. However, ticagrelor treatment has been associated with a potential increase in the serum uric acid (SUA) levels, which may influence endothelial dysfunction and prothrombotic status, thereby affecting the risk of acute cardiovascular events in patients requiring dual antiplatelet therapy (DAPT). The present study aimed to compare the impact of antiplatelet agents such as ticagrelor or clopidogrel on SUA levels and their effect on platelet reactivity.

AB - New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits. However, ticagrelor treatment has been associated with a potential increase in the serum uric acid (SUA) levels, which may influence endothelial dysfunction and prothrombotic status, thereby affecting the risk of acute cardiovascular events in patients requiring dual antiplatelet therapy (DAPT). The present study aimed to compare the impact of antiplatelet agents such as ticagrelor or clopidogrel on SUA levels and their effect on platelet reactivity.

KW - Clopidogrel

KW - Platelet aggregation

KW - Serum uric acid

KW - Ticagrelor

KW - Clopidogrel

KW - Platelet aggregation

KW - Serum uric acid

KW - Ticagrelor

UR - https://iris.uniupo.it/handle/11579/75748

U2 - 10.1016/j.numecd.2016.03.001

DO - 10.1016/j.numecd.2016.03.001

M3 - Article

SN - 1590-3729

VL - 26

SP - 567

EP - 574

JO - NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

JF - NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

IS - 7

ER -

Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this